logo-loader
viewBiocept Inc

Full interview: Biocept making great strides with its Switch-Blocker technology

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers in plasma circulating tumor DNA.

Nall says, along these lines, Biocept was recently awarded a patent on its Switch-Blocker technology in South Korea, bringing Biocept's patent total to 37.

Quick facts: Biocept Inc

Price: 0.771 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $17.75 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept making progress using artificial intelligence and...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H.C. Wainwright Global Investment Conference, drumming up investor excitement around the cancer diagnostics...

on 11/9/19

2 min read